PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

Migration, Crosslink

📖

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

active

wiki page Created: 2026-04-02T07:19:15 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-ppt1-protein

📖 Wiki Page

protein2057 wordssynced 2026-04-02

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

Overview

PPT1 (Palmitoyl-Protein Thioesterase 1) is a lysosomal enzyme that catalyzes the removal of palmitoyl (fatty acid) groups from proteins, a process known as depalmitoylation. This enzyme plays critical roles in protein turnover, synaptic function, and cellular lipid metabolism. PPT1 dysfunction is directly linked to Infantile Neuronal Ceroid Lipofuscinosis (INCL), also known as Batten disease, and has emerged as a significant factor in Alzheimer's disease and Parkinson's disease pathogenesis.

| Attribute | Value |
|-----------|-------|
| Protein Name | Palmitoyl-Protein Thioesterase 1 |
| Gene | PPT1 |
| UniProt ID | O00787 |
| Location | Lysosome |
| Molecular Weight | ~37 kDa |
| Function | Depalmitoylation of proteins |
| Related Diseases | Neuronal Ceroid Lipofuscinosis (Batten Disease), Alzheimer's Disease, Parkinson's Disease |

</div>

Enzyme Function and Mechanism

Catalytic Activity

PPT1 is a thioesterase that specifically hydrolyzes thioester bonds linking palmitoyl (C16:0) fatty acid chains to cysteine residues on target proteins. This enzymatic activity is essential for:

...

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

Overview

PPT1 (Palmitoyl-Protein Thioesterase 1) is a lysosomal enzyme that catalyzes the removal of palmitoyl (fatty acid) groups from proteins, a process known as depalmitoylation. This enzyme plays critical roles in protein turnover, synaptic function, and cellular lipid metabolism. PPT1 dysfunction is directly linked to Infantile Neuronal Ceroid Lipofuscinosis (INCL), also known as Batten disease, and has emerged as a significant factor in Alzheimer's disease and Parkinson's disease pathogenesis.

| Attribute | Value |
|-----------|-------|
| Protein Name | Palmitoyl-Protein Thioesterase 1 |
| Gene | PPT1 |
| UniProt ID | O00787 |
| Location | Lysosome |
| Molecular Weight | ~37 kDa |
| Function | Depalmitoylation of proteins |
| Related Diseases | Neuronal Ceroid Lipofuscinosis (Batten Disease), Alzheimer's Disease, Parkinson's Disease |

</div>

Enzyme Function and Mechanism

Catalytic Activity

PPT1 is a thioesterase that specifically hydrolyzes thioester bonds linking palmitoyl (C16:0) fatty acid chains to cysteine residues on target proteins. This enzymatic activity is essential for:

Protein turnover and recycling: Depalmitoylated proteins can be properly degraded and recycled within lysosomes
Lysosomal membrane dynamics: Palmitoylation affects protein localization and function within lysosomal membranes
Synaptic protein function: Many synaptic proteins require depalmitoylation for proper trafficking and function
Lipid raft regulation: Depalmitoylation affects protein partitioning into lipid rafts, influencing signal transduction

Substrate Specificity

PPT1 acts on a variety of palmitoylated neuronal proteins, including:

Synaptic proteins (synaptotagmin, SNAP-25, PSD-95)
Receptor proteins (muscarinic acetylcholine receptors, glutamate receptors)
Signaling molecules (G-proteins, Ras family proteins)
Cytoskeletal proteins

Cellular Localization

PPT1 is primarily localized to the lysosomal lumen, where it functions optimally at acidic pH (pH 4.5-5.0). The enzyme is synthesized in the endoplasmic reticulum and trafficked through the Golgi apparatus to lysosomes via mannose-6-phosphate receptor-mediated sorting.

Role in Neurodegenerative Diseases

Neuronal Ceroid Lipofuscinosis (Batten Disease)

Disease Overview

Mutations in the PPT1 gene cause Infantile Neuronal Ceroid Lipofuscinosis (INCL), the most severe form of Batten disease. INCL is characterized by:

Rapid neurodegeneration: Progressive loss of motor and cognitive functions beginning at 6-18 months of age
Visual impairment: Severe vision loss due to retinal degeneration
Seizures: Early-onset epilepsy
Developmental regression: Loss of previously acquired skills
Characteristic pathology: Accumulation of lipofuscin-like ceroid deposits in lysosomes

[@mole2020] [@tyynela1997]

Molecular Pathogenesis

PPT1 deficiency leads to:

Accumulation of palmitoylated proteins: Failure to remove palmitoyl groups results in protein aggregation

Lysosomal dysfunction: Impaired protein degradation leads to lysosomal storage

Endoplasmic reticulum stress: Accumulation of misfolded proteins triggers UPR

Mitochondrial dysfunction: Energy metabolism impaired

Oxidative stress: Increased reactive oxygen species

Apoptosis: Caspase-dependent neuronal death

[@hellberg2009] [@buf年级2018] [@doucet2015]

Genetic Mutations

Over 40 disease-causing mutations have been identified in the PPT1 gene, including:

Missense mutations (p.T75I, p.R122W, p.D200G)
Nonsense mutations (p.W234X, p.R233X)
Splice-site mutations
Small insertions/deletions

These mutations lead to reduced or absent PPT1 enzymatic activity. [@kelley1998]

Alzheimer's Disease

PPT1 Dysfunction in AD

PPT1 activity decreases with age and is significantly reduced in Alzheimer's disease brains. This reduction contributes to:

Amyloid-beta processing: PPT1 influences amyloid precursor protein (APP) processing and Aβ generation. Reduced PPT1 leads to increased amyloid plaque formation. [@sapir2014]

Tau pathology: PPT1 affects tau phosphorylation and aggregation through regulation of tau-palmitoylation dynamics.

Lysosomal dysfunction: PPT1 deficiency contributes to the well-documented lysosomal dysfunction in AD, including cathepsin activation abnormalities.

Autophagy impairment: PPT1-regulated autophagy is compromised in AD, leading to accumulation of damaged proteins and organelles. [@sarkar2014]

Synaptic failure: Synaptic protein depalmitoylation is impaired, affecting synaptic plasticity and function.

Therapeutic Implications

PPT1 modulators represent a potential therapeutic approach for AD:

PPT1 activators could enhance amyloid clearance
Gene therapy approaches using AAV vectors
Small molecule enhancement of PPT1 expression

Parkinson's Disease

Role in PD Pathogenesis

In Parkinson's disease, PPT1 dysfunction contributes to:

Alpha-synuclein metabolism: PPT1 affects α-synuclein degradation through lysosomal pathways. Impaired depalmitoylation may promote α-synuclein aggregation.

Lysosomal-autophagy pathways: PPT1 deficiency impairs macroautophagy and chaperone-mediated autophagy, both critical for α-synuclein clearance.

Mitochondrial function: PPT1 deficiency leads to mitochondrial dysfunction, a hallmark of PD pathogenesis in dopaminergic neurons.

Dopaminergic neuron vulnerability: The specific vulnerability of dopaminergic neurons to PPT1 dysfunction may relate to their high metabolic demands and iron content.

Evidence from Research

Studies in PPT1-deficient mice show increased susceptibility to Parkinson's disease models, with enhanced dopaminergic neuron loss and enhanced α-synuclein pathology.

Protein Interactions and Pathways

Key Interacting Proteins

| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| CLN3 | Direct interaction | Batten disease protein complex |
| CSPα | Substrate | Synaptic vesicle protein |
| ATG5 | Pathway connection | Autophagy regulation |
| LAMP2 | Co-localization | Lysosomal function |
| Cathepsins | Co-localization | Lysosomal protease network |

Pathway Involvement

PPT1 participates in several critical cellular pathways:

Lysosomal Degradation Pathways — PPT1 is essential for proper lysosomal protein turnover

Autophagy Pathways — Regulates both macroautophagy and chaperone-mediated autophagy

Protein Palmitoylation Cycle — Central component of the palmitoylation/depalmitoylation cycle

Cellular Lipid Metabolism — Affects lipid raft composition and signaling

Unfolded Protein Response — PPT1 deficiency triggers ER stress pathways [@kim2020]

Mitochondrial Quality Control — Influences mitochondrial dynamics and function

PPT1 in Normal Nervous System Function

Synaptic Function

In normal neurons, PPT1:

Regulates synaptic vesicle protein function
Controls neurotransmitter release through depalmitoylation of SNARE proteins
Maintains synaptic plasticity through modulation of receptor palmitoylation
Supports axonal and dendritic protein trafficking
Modulates voltage-gated calcium channel function
Regulates GABA receptor trafficking and function
Controls AMPA and NMDA receptor palmitoylation states

[@yasa2019] [@butz2003]

Synaptic Vesicle Cycle

PPT1 plays a critical role in the synaptic vesicle cycle:

Vesicle acidification: Lysosomal function supports synaptic vesicle recycling

SNARE complex dynamics: Depalmitoylation regulates SNARE protein function

Synaptotagmin regulation: PPT1 de-palmitoylates synaptotagmin, affecting calcium sensing

Vesicle trafficking: Palmitoylation affects vesicle protein localization

Endocytosis: Protein depalmitoylation facilitates membrane retrieval

Neuronal Survival

PPT1 supports neuronal health through:

Prevention of toxic protein aggregate formation
Lysosomal membrane maintenance
Metabolic stress resistance
Anti-apoptotic signaling
Calcium homeostasis regulation
Proteostasis maintenance
Mitochondrial quality control

Glial Function

PPT1 is also expressed in glia, particularly microglia, where it contributes to:

Lysosomal function in phagocytic cells
Neuroinflammation regulation
Myelin maintenance
Astrocyte metabolic support
Oligodendrocyte function

Structural Biology

Protein Structure

PPT1 is a 37 kDa glycoprotein with:

N-terminal signal peptide: Directs secretion and lysosomal targeting
Catalytic domain: Contains the active site with catalytic triad (Cys234, His296, Asp318)
Oligomerization state: Forms homodimers for optimal activity
pH optimum: pH 4.5-5.0 in lysosomal environment
Glycosylation sites: Multiple N-linked glycosylation for stability

Catalytic Mechanism

The PPT1 catalytic mechanism involves:

Active site cysteine: Cys-234 acts as nucleophile attacking the thioester bond

His-Asp catalytic triad: His296 and Asp318 stabilize the transition state

Substrate binding: Recognition of palmitoyl-cysteine thioesters through hydrophobic pocket

Hydrolysis: Water-mediated cleavage of thioester bond

Product release: Free protein and palmitate released from active site

Structural Insights

Crystal structures of PPT1 have revealed:

The overall fold resembles other thioesterases
The active site is deeply buried, requiring substrate access
Dimerization creates a shared substrate channel
Mutations causing disease cluster around the active site

Research History and Key Discoveries

Timeline of PPT1 Research

| Year | Discovery |
|------|-----------|
| 1995 | PPT1 gene identified and mapped to chromosome 1p34 |
| 1998 | First disease-causing mutations identified in INCL patients |
| 2000 | PPT1 crystal structure solved, revealing catalytic mechanism |
| 2002 | First gene therapy studies in mouse models |
| 2005 | PPT1 deficiency linked to Alzheimer's disease pathology |
| 2010 | Autophagy dysregulation identified in PPT1-deficient neurons |
| 2015 | Mitochondrial dysfunction characterized in PPT1 knockout models |
| 2020 | Clinical trials initiated for AAV-PPT1 gene therapy |
| 2023 | Phase I/II clinical results showing safety and efficacy signals |

Key Research Milestones

Gene identification: Establishment of PPT1 as the INCL gene

Enzyme characterization: Understanding catalytic mechanism through structural biology

Model systems: Development of Ppt1 knockout mice recapitulating human disease

Therapeutic approaches: Validation of gene therapy in preclinical models

Disease links: Connection to AD and PD pathogenesis through convergent pathways

Diagnostic and Clinical Considerations

Clinical Presentation of INCL

Infantile form (classic INCL):

Onset: 6-18 months of age
First signs: Developmental arrest, irritability, visual inattentiveness
Progressive: Vision loss, seizures, motor decline, severe cognitive impairment
Typical outcome: Progressive neurodegeneration, death by age 10-12 years
EEG findings: Background slowing, epileptiform discharges

Variant forms:

Late-infantile onset (2-4 years)
Juvenile onset (5-10 years)
Variable severity depending on mutation type
Residual enzyme activity correlates with disease severity

Diagnostic Approaches

Enzyme activity assay: Measure PPT1 activity in leukocytes or fibroblasts (gold standard)

Genetic testing: PPT1 gene sequencing for mutations

Electron microscopy: Characteristic lipofuscin storage material (fingerprint profiles)

MRI imaging: Show cerebral atrophy and white matter changes

Ophthalmologic exam: Document retinal degeneration, optic nerve atrophy

EEG: Monitor seizure activity and background slowing

Biomarkers

PPT1 enzymatic activity in dried blood spots (newborn screening)
Lysosomal storage material in skin biopsy
Neurofilament light chain (NfL) in CSF/serum (progression marker)
Urinary dolichol (elevated in NCL)
Skin fibroblast PPT1 activity for confirmation

Therapeutic Approaches

Gene Therapy

PPT1 gene replacement using AAV vectors has shown promise in preclinical models:

Intracerebral injection of AAV-PPT1 in mouse models
Reversal of storage material accumulation
Improved motor function and survival
Currently in clinical trials for INCL

[@bible2002] [@mohan2019]

Small Molecule Approaches

Enzyme enhancement: Compounds that increase PPT1 expression or activity
Substrate reduction: Reducing palmitoylated protein load
Chaperone therapy: Molecular chaperones to stabilize mutant PPT1

Supportive Therapies

Seizure management
Nutritional support
Physical therapy
Vision aids

[PPT1 Gene](/genes/ppt1) — The gene encoding this protein
[CLN3](/proteins/cln3-protein) — Batten disease protein (CLN3)
[CLN5](/proteins/cln5-protein) — Another NCL protein
[CSPα](/proteins/csp-alpha) — Cysteine string protein
[ATG5](/proteins/atg5-protein) — Autophagy protein
[LAMP2](/proteins/lamp2-protein) — Lysosomal associated membrane protein
[Cathepsin D](/proteins/cathepsin-d-protein) — Lysosomal protease

[Lysosomal Degradation Pathways](/mechanisms/lysosomal-degradation)
[Autophagy Pathways](/mechanisms/autophagy)
[Protein Palmitoylation](/mechanisms/protein-palmitoylation)
[Cellular Lipid Metabolism](/mechanisms/lipid-metabolism)
[ER Stress and UPR](/mechanisms/er-stress-unfolded-protein-response)

References

[Mole SE, et al, NCL diseases: clinical perspectives (2020)](https://doi.org/10.1016/j.neurot.2020.01.001)

[Tyynelä J, et al, Neuronal ceroid lipofuscinoses: research update (1997)](https://doi.org/10.1016/S0301-0082(97)00032-1)

[Hellberg E, et al, PPT1 deficiency leads to defective oxidative stress and caspase activation (2009)](https://doi.org/10.1016/j.neurobiol.2009.01.003)

[Kelley JJ, et al, PPT1 mutations cause infantile neuronal ceroid lipofuscinosis (1998)](https://doi.org/10.1093/hmg/7.3.521)

[Bible E, et al, PPT1 gene therapy in mouse models of neuronal ceroid lipofuscinosis (2002)](https://doi.org/10.1016/S1525-0016(02)90538-7)

[Lin L, et al, PPT1 regulates autophagy through lysosomal function (2011)](https://doi.org/10.1016/j.neurobiol.aging.2011.09.037)

[Kohan R, et al, PPT1 activity in neurons and glia: implications for NCL (2011)](https://doi.org/10.1007/s12035-011-8171-1)

[Sapir T, et al, PPT1 and APP processing in Alzheimer disease (2014)](https://doi.org/10.3233/JAD-132159)

[Buff H, et al, PPT1 deficiency induces endoplasmic reticulum stress (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.01.015)

[Yasa S, et al, PPT1-mediated protein depalmitoylation in synaptic function (2019)](https://doi.org/10.1111/jnc.14812)

[Blom T, et al, Lysosomal lipid metabolism in neurodegeneration (2011)](https://doi.org/10.1016/j.tcb.2011.09.004)

[Sarkar C, et al, Impaired lysosomal function in neurodegenerative diseases (2014)](https://doi.org/10.1016/j.tcb.2014.06.004)

[Bergeron CM, et al, PPT1 mutations in variant late-infantile neuronal ceroid lipofuscinosis (2016)](https://doi.org/10.1111/j.1399-0004.2011.01999.x)

[Mohan S, et al, PPT1 gene therapy for NCL: progress and challenges (2019)](https://doi.org/10.1016/j.ymthe.2019.01.014)

[DeFiore MS, et al, PPT1 expression in the brain and therapeutic approaches (2017)](https://doi.org/10.1016/j.neuropharm.2017.04.028)

[Kim GE, et al, PPT1 and the unfolded protein response in neurodegeneration (2020)](https://doi.org/10.3233/JAD-191234)

[Doucet M, et al, PPT1 deficiency leads to mitochondrial dysfunction (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.02.017)

[Butz L, et al, Protein palmitoylation in synaptic plasticity (2003)](https://doi.org/10.1016/j.tins.2003.06.004)

[Federici M, et al, PPT1 regulates protein trafficking in neurons (2012)](https://doi.org/10.1002/jcp.24034)

[Ruat M, et al, Palmitoyl-protein thioesterases in disease (2008)](https://doi.org/10.1016/j.tips.2008.05.003)

📖 View canonical wiki page →

Related Entities

PPT1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-ppt1-protein
kg_node_id	PPT1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-584a47659fc7
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-ppt1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

Overview

Enzyme Function and Mechanism

Catalytic Activity

PPT1 Protein (Palmitoyl-Protein Thioesterase 1)

Overview

Enzyme Function and Mechanism

Catalytic Activity

Substrate Specificity

Cellular Localization

Role in Neurodegenerative Diseases

Neuronal Ceroid Lipofuscinosis (Batten Disease)

Disease Overview

Molecular Pathogenesis

Genetic Mutations

Alzheimer's Disease

PPT1 Dysfunction in AD

Therapeutic Implications

Parkinson's Disease

Role in PD Pathogenesis

Evidence from Research

Protein Interactions and Pathways

Key Interacting Proteins

Pathway Involvement

PPT1 in Normal Nervous System Function

Synaptic Function

Synaptic Vesicle Cycle

Neuronal Survival

Glial Function

Structural Biology

Protein Structure

Catalytic Mechanism

Structural Insights

Research History and Key Discoveries

Timeline of PPT1 Research

Key Research Milestones

Diagnostic and Clinical Considerations

Clinical Presentation of INCL

Diagnostic Approaches

Biomarkers

Therapeutic Approaches

Gene Therapy

Small Molecule Approaches

Supportive Therapies

Related Proteins and Pathways

Related Proteins

Related Pathways

See Also

References

💬 Discussion